|The full article is available to subscribers||Subscriber Login|
Sumatriptan was first marketed in the US in 1993 as Imitrex for subcutaneous injection, followed by tablets for oral administration and then by a nasal spray. It is one of seven serotonin receptor agonists (“triptans”) marketed in the US for treatment of migraine, but it is the only one available for subcutaneous injection.1 Now the FDA has approved Sumavel DosePro (Zogenix), a needle-free device for delivering sumatriptan succinate to subcutaneous tissue, for treatment of migraine and cluster headache in adults.
DELIVERY — A nitrogen gas-powered injection pushes the drug through the skin to subcutaneous tissue within one-tenth of a second; delivery of the drug with this device is bioequivalent to injection through a needle.2
EFFICACY — Subcutaneous injections of sumatriptan act more rapidly than oral or intranasal modes... more